search
muscular dystrophy
Trends
- 1Penn researchers explore 'backup' protein to halt muscular dystrophy▼Stopping muscular dystrophy with a ‘backup’ protein
Researchers at Penn Medicine report that a so-called backup protein may be able to stop the progression of muscular dystrophy, a genetic disease that causes progressive muscle weakness. By stepping in for the faulty protein that patients lack, the substitute appears to protect muscle tissue from damage. The work points to a possible new treatment avenue for a condition with few options.
- 2Anthropic acquires Mithril Medicine, one-person AI biotech●Anthropic buys Mithril Medicine, a one-person biotech that ran a muscular dystrophy drug programme with Claude
Anthropic has bought Mithril Medicine, a biotech company run by a single person that used Claude to advance a drug programme targeting muscular dystrophy. The acquisition signals Anthropic's interest in applying its AI models to scientific discovery and drug development. Observers are watching what the deal means for AI-driven biotech and solo-founder companies built around large language models.
- 3Survey highlights mental health distress drivers in muscular dystrophy●Bionews survey highlights key drivers of mental health distress in MD
A survey by Bionews, reported by Muscular Dystrophy News, has identified the main factors driving mental health distress among people living with muscular dystrophy. The findings point to key challenges affecting patients' emotional wellbeing and are drawing attention to the need for better mental health support alongside medical care in the neuromuscular disease community.